title: Who should support the costs of severe adverse drug reactions?
authors.affiliation: Professor emeritus, University Paris Est Créteil (UPEC), 94010 Créteil, France.
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Roujeau
authors.affiliation: Chairman of AMALYSTE (SJS/TEN victims' association), 4 rue Yves Toudic, 75010 Paris, France http://amalyste.free.fr.
authors.forename: Sophie
authors.initials: S
authors.lastname: Le Pallec
references.citation: J Invest Dermatol. 2008 Jan;128(1):35-44
references.pmid: 17805350
references.citation: Am J Trop Med Hyg. 2006 May;74(5):738-43
references.pmid: 16687672
references.citation: N Engl J Med. 1995 Dec 14;333(24):1600-7
references.pmid: 7477195
references.citation: Pharmacogenet Genomics. 2008 Feb;18(2):99-107
references.pmid: 18192896
references.citation: JAMA. 1998 Apr 15;279(15):1200-5
references.pmid: 9555760
references.citation: J Clin Epidemiol. 1996 Jul;49(7):769-73
references.pmid: 8691227
references.citation: Nature. 2004 Apr 1;428(6982):486
references.pmid: 15057820
references.citation: J Am Acad Dermatol. 2008 Jan;58(1):33-40
references.pmid: 17919775
references.citation: Br Med J (Clin Res Ed). 1982 May 15;284(6327):1457-9
references.pmid: 6211213